RYR2 and head and neck cancer: One TCGA database analysis revealed frequent somatic mutations and aberrant promoter methylation and reduced expression of RYR2 in head and neck cancer, suggesting that reduced RYR2 expression in adjacent tissue and precancerous lesions might serve as risk factor for unfavorable prognosis and malignant conversion5.